EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells

Nicola Landi, Vincenza Ciaramella, Sara Ragucci iD, Angela Chambery iD, Fortunato Ciardiello, Paolo V Pedone, Teresa Troiani, Antimo Di Maro iD

Toxins · 2023

DOI: 10.3390/toxins15010057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2023. Verfasst von Nicola Landi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania 'Luigi Vanvitelli', Via Vival…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colonic Neoplasms, Colorectal Neoplasms, Immunotoxins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Campania “Luigi Vanvitelli”, project BIONUTRA—PON 2014–2020 (Development of Nutraceuticals from Natural Sources).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cetuximab is a monoclonal antibody blocking the epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC). However, cetuximab treatment has no clinical benefits in patients affected by mCRC with KRAS mutation or in the presence of constitutive activation of signalling pathways acting downstream of the EGFR. The aim of this study was to improve cetuximab’s therapeutic action by conjugating cetuximab with the type 1 ribosome inactivating protein (RIP) quinoin isolated from quinoa seeds. A chemical conjugation strategy based on the use of heterobifunctional reagent succinimidyl 3-(2-pyridyldithio)propionate (SPDP) was applied to obtain the antibody-type 1 RIP chimeric immunoconjugate. The immunotoxin was then purified by chromatographic technique, and its enzymatic action was evaluated compared to quinoin alone. Functional assays were performed to test the cytotoxic action of the quinoin cetuximab immunoconjugate against the cetuximab-resistant GEO-CR cells. The novel quinoin cetuximab immunoconjugate showed a significant dose-dependent cytotoxicity towards GEO-CR cells, achieving IC50 values of 27.7 nM (~5.0 μg/mL) at 72 h compared to cetuximab (IC50 = 176.7 nM) or quinoin (IC50 = 149.3 nM) alone assayed in equimolar amounts. These results support the therapeutic potential of quinoin cetuximab immunoconjugate for the EGFR targeted therapy, providing a promising candidate for further development towards clinical use in the treatment of cetuximab-resistant metastatic colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColonic NeoplasmsColorectal NeoplasmsImmunotoxinsHumansAntibodies, Monoclonal, HumanizedCetuximabErbB ReceptorsMutationSaporinsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Chenopodium quinoaGEO-CR cellschemical conjugationcytotoxicitymonoclonal antibody

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabEGFR protein, humanErbB ReceptorsImmunotoxinsSaporins

Autor:innen und Institutionen

  • Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania 'Luigi Vanvitelli', Via Vivaldi 43, 81100 Caserta, Italy.
  • Medical Oncology, Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Via S. Pansini 5, 80131 Napoli, Italy.

ORCID-Profile: Sara Ragucci, Angela Chambery, Antimo Di Maro

Förderung

  • University of Campania “Luigi Vanvitelli”
  • project BIONUTRA—PON 2014–2020 (Development of Nutraceuticals from Natural Sources)

Zitieren

APA

Landi, N., Ciaramella, V., Ragucci, S., Chambery, A., Ciardiello, F., Pedone, P. V., Troiani, T., & Di Maro, A. (2023). A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. Toxins. https://doi.org/10.3390/toxins15010057

Vancouver

Landi N, Ciaramella V, Ragucci S, Chambery A, Ciardiello F, Pedone PV, et al. A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. Toxins. 2023. doi:10.3390/toxins15010057

BibTeX
@article{Landi2023,
  author = {Landi, Nicola and Ciaramella, Vincenza and Ragucci, Sara and Chambery, Angela and Ciardiello, Fortunato and Pedone, Paolo V and Troiani, Teresa and Di Maro, Antimo},
  title = {A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells},
  journal = {Toxins},
  year = {2023},
  doi = {10.3390/toxins15010057}
}
Kostenlos starten →